Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 Per Share Plus Contingent Value Right — Cooley Advises Kezar

"Kezar Life Sciences, a biotech developing small-molecule therapies for autoimmunity and cancer, has agreed to be acquired by Aurinia Pharmaceuticals for $6.955 per share in cash plus one non-transferable contingent value right. Cooley advised Kezar on the transaction; the lead Cooley advisers were Bill Roegge, Rita Sobral, Laura Berezin, Jaime Chase and Parth Bhatt. Cooley had previously represented Kezar in its $50 million Series B (2017), $75 million IPO (2018), and in responding to an unsolicited takeover proposal, including adoption of a shareholder rights plan."